Core Insights - Honeywell has been selected by Bell Textron Inc. to provide its 36-150 auxiliary power unit (APU) and Honeywell Attune™ system for the U.S. Army's Future Long-Range Assault Aircraft (FLRAA) [1][3] - The 36-150 APU enhances aircraft mission readiness by providing a secondary source of electrical and hydraulic power, while Honeywell Attune™ is a lightweight, low-maintenance thermal management system [2][4] - Honeywell's 36-150 APU has a proven track record with over 10,000 units delivered for various applications, demonstrating reliability and fuel efficiency [3] Product Features - The 36-150 APU is a derivative of a successful model series known for its reliability and fuel efficiency, currently in use in the Army's UH-60 Black Hawk and AH-64 Apache helicopters [3] - Honeywell Attune™ is designed to be up to 35% lighter and 20% more efficient than traditional cooling systems, providing significant advantages in weight, size, and power [4] - The system utilizes Honeywell's Solstice zd refrigerant, making it an environmentally-friendly option for aircraft cooling [5] Strategic Alignment - Honeywell's technologies align with three megatrends: automation, the future of aviation, and energy transition, showcasing the company's commitment to innovation and sustainability [7] - The selection of Honeywell's systems for the FLRAA contract indicates a long-term partnership with the U.S. Army, expected to last beyond 2050 [3]

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors about its business prospects, particularly regarding customer spending and revenue impacts from updated milestone criteria in its Regenerative Medicine Program [1][2]. Financial Performance - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million. The company also reported a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, worse than the consensus estimate of a loss of $0.14 per share, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The company withdrew its full-year 2025 outlook due to prolonged softness in customer capital spending and macroeconomic uncertainty, resulting in a further stock price decline of $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].

Core Viewpoint - Falcon Oil & Gas Ltd has announced a significant achievement in the Beetaloo Sub-basin, with the Shenandoah S2-2H ST1 well recording an average 30-day initial production (IP30) flow rate of 7.2 million cubic feet per day (MMcf/d), marking the highest IP30 result in the region to date [2][5]. Development Activity - The IP30 flow rate of 7.2 MMcf/d exceeds Falcon's pre-drill commercial threshold of 3 MMcf/d per 1,000 metres, indicating strong resource potential in the Beetaloo Sub-basin [5]. - The normalized flow rate of 13.2 MMcf/d over an extrapolated 10,000-foot horizontal section aligns with the average of over 11,000 wells in the Marcellus Shale dry gas area [6]. - The exit rate trajectory shows a steady decline at 6.7 MMcf/d, with a flowing wellhead pressure of approximately 910 psi, consistent with previous wells in the area [6]. - Falcon plans to complete and test the SS-4H well by the end of 2025, with a drilling campaign for three additional wells set to commence in July 2025 [6]. - The five wells on the SS2 pad are expected to be tied into the Sturt Plateau Compression Facility under a 40 MMcf/d take-or-pay Gas Sales Agreement with the Northern Territory Government, with production anticipated to start in mid-2026 [6].

Disclosure of trading in own shares occurred from June 9 to June 13, 2025 Saint-Cloud, June 16, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 9 to June 13, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily ...

DIVERSIFIED ENERGY COMPANY PLC(the “Company") Q4 2024 Dividend Exchange Rate BIRMINGHAM, Ala. , June 16, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC (LSE:DEC, NYSE:DEC) announced on April 9, 2025 a dividend in respect of the fourth quarter ended December 31, 2024 in the amount of 29 cents per share (the “Q4 2024 Dividend”.) The Company will pay the Q4 2024 Dividend on June 30, 2025 to those shareholders on the register on May 30, 2025. The Company announces that shareholders who have elected ...

Continuing strong momentum supports increased confidence and FY 2025 guidance upgradeJERSEY CITY, N.J., June 16, 2025 /PRNewswire/ -- BetMGM LLC ("BetMGM"), one of the leading sports betting and iGaming operators across North America, jointly owned by MGM Resorts International (NYSE: MGM) ("MGM Resorts") and Entain plc (LSE: ENT) ("Entain"), is today providing an update to FY 2025 guidance. This announcement is being made by BetMGM as a consequence of Entain plc's required regulatory disclosure to the marke ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been nearly a year since my last Sarepta Therapeutics (NASDAQ: SRPT ) article , when the ticker was trading near $160 per share. At that time, Sarepta was riding high on the FDA’s landmark expanded approval ofHe is the leader of the investing grou ...

Company announcement no. 34 / 2025Schindellegi, Switzerland – 16 June 2025 Trifork Group: Weekly report on share buyback On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. For details, please see company announcement no ...

Core Points - Jyske Bank has initiated a share repurchase program that will run from February 26, 2025, to January 30, 2026, with a total value of up to DKK 2.25 billion [1] - The program is structured in compliance with the EU Market Abuse Regulation and Safe Harbour Rules [1] Summary of Transactions - As of the latest announcement, Jyske Bank has repurchased a total of 1,025,529 shares at an average price of DKK 541.18, amounting to a total transaction value of DKK 554,995,995 [2] - The accumulated shares prior to the latest transactions were 982,403 shares at an average price of DKK 537.23, totaling DKK 527,780,007 [2] - The share repurchase program has resulted in Jyske Bank owning 1.67% of its share capital [2]

Core Insights - The article reflects on a past investment in Galapagos and the impact of FDA decisions on stock performance, highlighting the risks associated with pharmaceutical investments [1] - The author emphasizes the importance of specific investment criteria, including revenue growth, earnings growth, free cash flow, and favorable valuations [1] Investment Criteria - Companies should demonstrate growth in revenue, earnings, and free cash flow [1] - Excellent growth prospects are essential for potential investments [1] - Favorable valuations are a key consideration for stock selection [1] - Preference is given to companies with high free cash flow margins, dividend stocks, and those with generous share repurchase programs [1]